Study guide
6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine
Oregon Multistate Pharmacy Jurisprudence Examination MPJE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Oregon Legal Framework
1.1 Oregon MPJE Format, Fees, Blueprint & 2027 Changes 1.2 Federal–Oregon Legal Hierarchy, Agencies & the Board of Pharmacy
2 Chapter 2: Pharmacist & Pharmacist-in-Charge Responsibilities
2.1 Pharmacist Responsibilities, Supervision & Prohibited Practices 2.2 Pharmacist-in-Charge: Qualifications, Duties, Inventories & Self-Inspection
3 Chapter 3: Pharmacy Technicians, Interns & Preceptors
3.1 Pharmacy Technicians (COPT & PT): Licensure, Permitted Tasks & Limits 3.2 Pharmacy Interns & Preceptors: Licensure, Scope & Supervision
4 Chapter 4: Licensure, Renewal, Discipline & Impaired Practitioners
4.1 Pharmacist Licensure by Examination, Score Transfer & Reciprocity 4.2 License Renewal, Continuing Pharmacy Education & Lapse Rules 4.3 Grounds for Discipline, Sanctions & Mandatory Reporting Deadlines 4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)
5 Chapter 5: Prescriber Authority & Prescription Requirements
5.1 Prescriber Authority, DEA Registration & Out-of-State Prescriptions 5.2 Non-Controlled Prescriptions: Required Elements, Signatures, Expiration & Refills 5.3 Controlled Substance Prescriptions: Schedules II–V, EPCS, Emergency Orders & Oregon's CV Limit 5.4 Drug-Use Limitations & Special Prescriptions: REMS, Death with Dignity, EPT & Standing Orders 5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags
6 Chapter 6: Pharmacist Clinical Services & Prescriptive Authority
6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing 6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements 6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689) 6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing 6.5 Vaccine Prescribing & Administration: Age Floors, Protocols, Training & ALERT IIS 6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine
7 Chapter 7: Counseling, Language Access & Confidentiality
7.1 Patient Counseling: Triggers, Who May Offer or Accept a Refusal & Documentation 7.2 Language Access & Accessibility: Dual-Language Labels, Registry Interpreters & Prescription Readers 7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy
8 Chapter 8: The Dispensing Process
8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It 8.2 Oregon PDMP: Reporting Within 72 Hours, Covered Drugs, Access & Confidentiality 8.3 Prescription Transfers: Oregon's Next-Business-Day Duty & Federal Controlled Substance Limits 8.4 Dispensing Exceptions: 72-Hour Emergency Refills, Continuation of Therapy, Insulin & Declared Emergencies 8.5 Partial Fills: Schedule II (72-Hour, 30-Day CARA & 60-Day LTCF/Terminal) and Schedules III–V 8.6 Prescription Labeling: Oregon Elements, Physical Description, Expiration Dating & Med Paks 8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule 8.8 Conditions Prohibiting Dispensing, Quarantine, Returned Drugs & Charitable Reuse
9 Chapter 9: Nonprescription & Restricted Products
9.1 Nonprescription Drugs: Outlet Registration, Drug Facts Labeling & OTC Packaging 9.2 Dispensing-Restricted Nonprescription Products: Pseudoephedrine, Exempt Schedule V & Others
10 Chapter 10: Product Selection: Generic & Biologic Substitution
10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)
11 Chapter 11: Acquisition, Records, Inventories & Loss Reporting
11.1 Ordering & Acquiring Controlled Substances: DEA Registration, Form 222, CSOS & the 5% Rule 11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention 11.3 Controlled Substance Inventories: Oregon's 367-Day, 93-Day, 31-Day & 15-Day Rules 11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles
12 Chapter 12: Pharmacy Operations, Storage, Security & Special Practice Settings
12.1 Pharmacy Operations: Pharmacist Presence, Policies, Equipment, Signage, Hours & Closures 12.2 Drug Storage & Cold Chain: Temperatures, Monitoring Plans, Excursions & Vaccine Units 12.3 Security & Non-Pharmacist Access: Keys, Double Set-Ups, Institutional Night Access & DEA Controls 12.4 Hazardous Drugs: NIOSH 2024 List, USP 800 Controls, Assessment of Risk & Disposal 12.5 Compounding: OAR 855-183 (June 2026), USP 795/797/800, 503A vs. 503B & Beyond-Use Dates 12.6 Delivery of Drugs: Depots, Mail Delivery, Prescription Lockers, Kiosks & Mobile Pharmacies 12.7 Central Fill, Remote Processing, Telework & Remote Dispensing Site Pharmacies
13 Chapter 13: Drug Outlet Registration, Inspection & Institutional Practice
13.1 Drug Outlet Classes, Registration, Changes of Ownership/Location/Name & Non-Resident Pharmacies 13.2 Inspections, Self-Inspection Forms & Discipline of Drug Outlets 13.3 Institutional & Long-Term Care Practice: Drug Rooms, Night Access, E-Kits, ADCs & ED Prepacks
6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine
Key Takeaways Explain This Topic AI
Oregon pharmacists may prescribe naloxone or another short-acting opioid antagonist when dispensing opioids above 50 MME, to any individual who seeks it and to entities (OAR 855-115-0350).
Under ORS 689.808, an Oregon pharmacist shall dispense an opioid antagonist on request pursuant to OHA's standing order, and good-faith distribution or use is immune unless wanton.
Oregon retail and hospital outpatient pharmacies must post conspicuous notice that opioid antagonists are available, and opioid antagonist dispensing is not reported to the PDMP.
ORS 475.898 protects both the 911 caller and the overdosing person from arrest or prosecution for listed possession offenses discovered because of the call.
Oregon pharmacists may prescribe MOUD under a protocol or CDTM, but the protocol requires 8 hours of OUD training and a DEA registration covering Schedule III.
Last updated: October 2026
Why this matters
Oregon treats overdose prevention as core pharmacy practice. Short-acting opioid antagonist (SAOA) law moved from the old ORS 689.681 series to ORS 689.800–689.813 in 2023. The Board's prescribing rule is OAR 855-115-0350 , and a separate statute authorizes pharmacist prescribing of medications for opioid use disorder (MOUD) (ORS 689.698). The MPJE tests when pharmacists may or must provide naloxone, who may receive it, liability protections, and the DEA requirement for MOUD.
Short-acting opioid antagonists
A short-acting opioid antagonist is any short-acting FDA-approved drug for the complete or partial reversal of an opioid overdose, such as naloxone nasal spray or injection, or nalmefene nasal spray (ORS 689.802(1)(c)).
When a pharmacist may prescribe (ORS 689.802; OAR 855-115-0350)
An Oregon pharmacist may prescribe an FDA-approved SAOA and the supplies needed to administer it:
When dispensing an opioid prescription above 50 morphine milligram equivalents (MME) . The pharmacist may offer to prescribe and provide naloxone along with the opioid.
To an individual seeking an SAOA : a person at risk, or a family member, friend or bystander.
To an entity seeking an SAOA , such as a school, shelter or business.
The pharmacist documents the encounter under OAR 855-104-0055. Nasal-spray SAOA products are exempt from certain labeling requirements (ORS 689.813; OAR 855-115-0350). Separately, any person may buy OTC naloxone nasal spray (approved for nonprescription sale in 2023) without a prescription.
Standing orders and the duty to dispense (ORS 689.808)
OHA's Public Health Officer , or an OHA-employed physician, may issue a statewide or regional standing order for an SAOA and supplies for:
People at risk of overdose.
People or entities who may encounter someone at risk.
Owners of public buildings.
Upon the request of an individual or entity, a pharmacist shall dispense an SAOA pursuant to the standing order. A person acting in good faith who possesses, distributes or administers under the standing order is immune from civil and criminal liability unless the conduct is wanton misconduct. They are also immune for declining to do so.
Notice and public access
Every retail and hospital outpatient pharmacy must post conspicuous written notice that an SAOA and supplies are available (ORS 689.806; OAR 855-041-1035).
Owners of buildings with public access may keep SAOA kits obtained under a standing order. Members of the public who administer one in good faith are immune (ORS 689.811).
Social services agency employees, such as shelter staff, and school personnel trained under State Board of Education rules may administer an SAOA not distributed to them (ORS 689.804).
Good Samaritan protection (ORS 475.898)
A person who contacts emergency medical services or police for someone experiencing a drug-related overdose, and the person experiencing the overdose, are immune from arrest, prosecution or civil penalty for listed possession offenses when the evidence was obtained because of the call. The offenses include possession of controlled substances, of specified opioids and stimulants, of prescription drugs without a prescription, and of paraphernalia. The immunity also covers probation and release violations based on that evidence. It does not cover other crimes, such as delivery or manufacturing.
PDMP
SAOA dispensing is excluded from Oregon PDMP reporting (ORS 431A.855(4)).
Medications for opioid use disorder (ORS 689.698)
An Oregon pharmacist may prescribe, dispense and administer MOUD under:
a statewide protocol developed by the PHPFAC with an addiction-medicine physician and adopted by the Board, or
a CDTM agreement .
Because buprenorphine products are Schedule III , a pharmacist may register with DEA as a mid-level practitioner to prescribe Schedule II–V MOUD (ORS 689.698(2)). The Board's MOUD Initiation and Continuation/Modification protocols (v. 02/2026) require:
Eight hours of ACPE-accredited OUD training , including MOUD prescribing, before applying for DEA registration.
A current DEA registration for Schedule III.
The standardized intake forms and care pathways, and a required patient instruction sheet for initiation.
A pharmacist-prescribed MOUD prescription may be transmitted electronically to a different dispensing pharmacist (ORS 475.188). Since the federal X-waiver requirement was eliminated in 2023, any DEA practitioner registration that includes Schedule III covers buprenorphine for OUD, subject to the DEA training attestation for new or renewing registrants.
Important
Naloxone prescribing needs no DEA registration , because naloxone is not a controlled substance. Buprenorphine prescribing by a pharmacist requires DEA registration on top of the Oregon protocol authority.
Exam scenario
A patient fills oxycodone 10 mg every 6 hours (60 MME/day). The pharmacist may offer to prescribe naloxone under OAR 855-115-0350, because the prescription exceeds 50 MME, and documents the encounter. The patient's roommate later comes in alone and asks for naloxone. The pharmacist may prescribe it to the roommate, or must dispense it if the request is made under OHA's standing order. Nothing is reported to the PDMP. If the patient later asks the pharmacist to start buprenorphine, the pharmacist may do so only after the 8 hours of training, with a DEA registration covering Schedule III, and by following the MOUD initiation protocol.